RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

OT (TRGT) Any company with $90 million in cash has the 'potential for recovery.' But having resisted suggestions to diversify beyond nicotinics for the past four or five years, they are now having to figure out how to proceed in a post-nicotinic environment (for them, and for most, albeit not all, of their competitors). They don't yet know where to go in terms of inlicensing/M&A, but they know they cannot afford another misstep, $90 million doesn't go as far as it used to. I wouldnt bet on it being spent on a CNS program(s), though they tell me that is still a possibility.

NeuroPerspective